FTSE 100 shares swing but close below 7200
FTSE 100 shares swung on Friday but ended down 10 points and below 7200 as the 45th President of the United States was being sworn in
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1084 stories · page 45 of 55
AstraZeneca rejigs MYSTIC lung cancer study
The ‘pivotal’ study will now look at overall survival rather than just progression-free survival
FTSE 100 shares hit 11th successive record high as sterling dips
FTSE 100 shares did it again on Thursday – the 11th successive record high close – as turbulence in sterling finally gave in to a further steady decline and helped push stocks higher. All except retailers, that is
Sirius Minerals named among the ‘top tips’ for 2017
Here we take a look at the medium and small cap companies included among Fleet Street's top stock market tips for 2017.
Brexit and Trump key to how 2017 unfolds
Richard Hunter is keeping tabs on AstraZeneca, GSK and ITV as we head into 2017
Investments and investor services
FTSE 100 ends above 7,000 for first time since late October
FTSE 100 shares closed back above 7,000 on Friday for the first time since late October
AstraZeneca cancer drug application accepted by FDA
AstraZeneca’s application to use its closely-watched new drug durvalumab to treat bladder cancer has been accepted by US regulator, the Food and Drug Administration
AstraZeneca top pick under UBS's new valuation method
The conventional forecasting tool-box is broken says the Swiss broker
FTSE 100 stocks march higher, miners lead
FTSE 100 stocks marched higher on Wednesday with miners the top gainers
Five reasons to buy AstraZeneca
The general consensus is that the decline in AstraZeneca’s share price now represents a good buying opportunity
AstraZeneca's MYSTIC trial has little appeal for JP Morgan
The broker’s target price drops to £46 from £49 and the rating remains hold.
AztraZeneca a bargain, says this stock picker
The unwinding of bid speculation has meant AZ has lost around 15% of its value in the last six months.
FTSE 100 closed firm but volumes thin
FTSE 100 shares managed to recover enough to close Friday firmer but volumes were held back by the half-day trading in New York following Thanksgiving holiday on Thursday
AstraZeneca restarts cancer drug trials after US all clear
The two trials, KESTREL and EAGLE, are for head and neck cancer sufferers
Is too great a risk of MYSTIC failure factored into AstraZeneca's price?
Berenberg ascribes a 75% chance of success for the MYSTIC first-line lung cancer study, whereas the market seems more sceptical
It's all about the pipelines for drugs giants Astra and Shire
Exane has a target price of 5,100p for Astra, versus a current price of 4,406p. DB’s valuation of 6,200p per share for Shire is more than a tenner above the current price of around 5,020p.
AstraZeneca trial shows benefit of child asthma treatment
The improvement demonstrated the drug's appropriateness as a step-up therapy in young children
Immuno-therapy trials key for AstraZeneca says broker
Astra’s revenues fell 4% in the three months to September to US$5.7bn
AstraZeneca a highlight for a busy City schedule for Thursday
AstraZeneca, Vedanta, Halfords, and SuperGroup were among those in Thursday's diary.